Humacyte Faces Fresh Nasdaq Delisting Notice as Stock Again Dips Below $1.00
HUMA sits 21% above its 52-week low of $0.547 on light trading volume (0.2× avg).
Summary
On July 31, 2026, Humacyte received a Nasdaq delisting notice after its stock closed below $1.00 for 30 consecutive days. The company has until January 27, 2027, to regain compliance. This is the second such notice in three months, highlighting ongoing listing risk.
Key Events · Legal and Risk Events · HUMA
-
Second Nasdaq Delisting Notice in 3 Months
On July 31, 2026, Nasdaq notified Humacyte that its stock had closed below $1.00 for 30 consecutive business days, triggering a new 180-day compliance period that ends on January 27, 2027. The company had previously regained compliance on June 5, 2026, after a similar notice in May.
-
Compliance Deadline: January 27, 2027
To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days before the deadline. Failure to do so could result in delisting from the Nasdaq Global Select Market.
-
Persistent Listing Risk Amid Financial Distress
The new notice compounds existing risks: a going concern warning, a $17.6M Q1 net loss, and a stock price of $0.66—well below the $1.00 threshold. Maintaining its listing may require a reverse stock split or additional dilutive financing.
-
Recent Positive Developments Overshadowed
The delisting notice follows positive Phase 3 clinical data for ATEV in June and a $50M public offering priced at $1.05 per share, but the stock has since declined, reflecting ongoing market concerns about cash burn and dilution.
Analysis · HUMA · Life Sciences
Nasdaq has notified Humacyte that its stock price has once more fallen short of the $1.00 minimum bid requirement, starting a new 180-day compliance clock that runs through January 27, 2027. This marks the second such notice in three months—the company had only regained compliance in early June after a prior deficiency. The recurrence underscores persistent market skepticism, even after recent positive clinical data and a $50 million capital raise. With a going concern warning already in place and the stock trading at $0.66, the delisting risk is acute and could force a reverse stock split or further dilutive financing.
At the time of this filing, HUMA was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176.2M. The 52-week trading range was $0.55 to $2.76. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.